Sophia Genetics SA (SOPH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sophia Genetics SA (SOPH) has a cash flow conversion efficiency ratio of -0.145x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.79 Million) by net assets ($60.69 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sophia Genetics SA - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Sophia Genetics SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Sophia Genetics SA for a breakdown of total debt and financial obligations.
Sophia Genetics SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sophia Genetics SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sandhar Technologies Limited
NSE:SANDHAR
|
0.077x |
|
Iljin Holdings
KO:015860
|
0.059x |
|
Jay Mart Public Company Limited
BK:JMART
|
0.025x |
|
Wuhan Golden Laser Co Ltd
SHE:300220
|
0.121x |
|
Goody Science & Technology Co Ltd
SHE:002694
|
0.014x |
|
Energy One Ltd
AU:EOL
|
0.115x |
|
Peach Property Group AG
SW:PEAN
|
-0.012x |
|
PI Advanced Materials Co. Ltd
KQ:178920
|
0.051x |
Annual Cash Flow Conversion Efficiency for Sophia Genetics SA (2019–2024)
The table below shows the annual cash flow conversion efficiency of Sophia Genetics SA from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see SOPH stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $96.49 Million | $-42.82 Million | -0.444x | -38.36% |
| 2023-12-31 | $151.44 Million | $-48.58 Million | -0.321x | +8.42% |
| 2022-12-31 | $200.13 Million | $-70.09 Million | -0.350x | -66.48% |
| 2021-12-31 | $275.40 Million | $-57.94 Million | -0.210x | +33.36% |
| 2020-12-31 | $100.51 Million | $-31.73 Million | -0.316x | +77.82% |
| 2019-12-31 | $22.25 Million | $-31.68 Million | -1.424x | -- |
About Sophia Genetics SA
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutic… Read more